NCT06492538

Brief Summary

The drainage angle in the anterior chamber of the eye mediates the outflow of aqueous humor, and pathological changes here can lead to high intraocular pressure and glaucoma. Minimally invasive glaucoma surgery, particularly angle surgery, has advanced recently, allowing clear visualization of angle structures like the trabecular meshwork and Schlemm's canal using surgical goniolens. Techniques for angle intervention include widening the angle, reopening closed angles, and rebuilding outflow pathways using methods such as laser peripheral iridotomy, Argon laser peripheral iridoplasty, and mechanical separation of adhered tissues. Our research team plans to conduct imaging studies to track the healing of angle tissues post-surgery, aiming to support innovation and standardization of minimally invasive angle surgery.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 1, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 9, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

December 12, 2025

Status Verified

October 1, 2025

Enrollment Period

2.1 years

First QC Date

July 1, 2024

Last Update Submit

December 4, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in biological parameters of the anterior chamber angle

    Biological parameter changes in the anterior chamber following angle intervention surgery will be measured using Casia2-OCT

    12 months

Secondary Outcomes (1)

  • success rate of angle intervention surgeries

    12 months

Other Outcomes (1)

  • safety of angle intervention surgeries

    1 months

Study Arms (5)

laser peripheral iridotomy/iridoplasty group

based on angle closure mechanism, procedures were chosen LPI alone or combined with ALPIp. LPI: laser peripheral iridotomy; ALPIp: argon laser peripheral iridoplasty.

Procedure: various types of angle interventions

peripheral iridectomy based surgery combo

SPI combined with GSL or GSL+GT SPI: surgical peripheral iridectomy GSL:goniosynechialysis GT: goniotomy GSL and GT are both guided by surgical goniolens

Procedure: various types of angle interventions

phacoemulsification and intraocular lens implantation based surgery combo

PEI: phacoemulsification and intraocular lens implantation surgery combo includes GSL alone or GSL+GT.

Procedure: various types of angle interventions

ab interno goniotomy

GT was performed in the nasal-inferior quadrant or nasal quadrant because the collector channels were mainly concentrated in the nasal quadrant, by inserting the tip of a microblade (TMH; Tanito Microhook, Inami \& Co., Ltd., Tokyo, Japan) into Schlemm's canal, and then the inner wall of Schlemm's canal and trabecular meshwork was incised over 120°

Procedure: various types of angle interventions

Schlemm canaloplasty

performed in the nasal quadrant by the collector channels were mainly concentrated in the nasal quadrant, by inserting the tip of a microblade (TMH; Tanito Microhook, Inami \& Co., Ltd., Tokyo, Japan) into Schlemm's canal, and then the inner wall of Schlemm's canal and trabecular meshwork was incised over 120°

Procedure: various types of angle interventions

Interventions

procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor. Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.

Schlemm canaloplastyab interno goniotomylaser peripheral iridotomy/iridoplasty groupperipheral iridectomy based surgery combophacoemulsification and intraocular lens implantation based surgery combo

Eligibility Criteria

Age30 Years - 85 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with glaucoma typically present with: IOP \> 21 mmHg with or without the use of ocular hypotensive medications; (3) with obvious glaucomatous optic neuropathy \[cup-to-disc (C/D) ratio ≥ 0.7, C/D ratio asymmetry \> 0.2, or rim width at the superotemporal and inferotemporal \< 0.1 vertical diameter of the optic disc\], and glaucomatous visual field defects, such as nasal step, arcuate scotoma, and paracentral scotoma;

You may qualify if:

  • Glaucoma patients eligible for standalone or combined angle intervention surgeries, such as LPI, LPIP, goniosynechialysis, trabeculotomy alone or combined with surgical iridectomy or phacoemulsification and intraocular lens implantation;
  • Patients capable of undergoing preoperative examinations including CASIA2-OCT (anterior segment OCT), UBM, slit-lamp gonioscopy, IOL Master (or other optical biometry);
  • Patients willing to participate in this study, signing informed consent, and agreeing to follow-up according to the study protocol.

You may not qualify if:

  • Patients with severe ocular conditions such as corneal infection, ulcer, trauma, ocular tumors, retinal vascular occlusion, and retinal detachment;
  • Those with various types of eye diseases that affect ocular parameter acquisition or interfere with visual field examination;
  • Long-term local or systemic use of glucocorticoids;
  • Patients with severe systemic diseases;
  • Pregnant or lactating women;
  • Unable to complete 12-month postoperative follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan ophthalmic center

Guangzhou, Guangdong, 51006dddddd0, China

RECRUITING

MeSH Terms

Conditions

Glaucoma, Angle-ClosureGlaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Study Officials

  • Xinbo Gao, MD

    State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate professor

Study Record Dates

First Submitted

July 1, 2024

First Posted

July 9, 2024

Study Start

December 1, 2023

Primary Completion

December 30, 2025

Study Completion

December 30, 2025

Last Updated

December 12, 2025

Record last verified: 2025-10

Locations